BioSpace News Archive

iSpecimen Inc. today announced that it has entered into a definitive securities purchase agreement for a private placement with three accredited investors for the sale of 1,749,999 shares of common stock of iSpecimen.

Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration has approved its Investigational New Drug application for AVA6000.

The largest multi-institutional international study to date on brain complications of COVID-19 has found that approximately one in 100 patients hospitalized with COVID-19 will likely develop complications of the central nervous system.

Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced the appointment of Mr. Yiqing Chen as Chief Financial Officer, reporting directly to Dr. Dajun Yang, Chairman and Chief Executive Officer of Ascentage Pharma.

Dialysis patients who received mRNA COVID-19 vaccines had a lower risk of COVID-19 diagnosis post-vaccination and were less likely to be hospitalized or die following breakthrough infection than unvaccinated patients, according to a DaVita Clinical Research study published online ahead of print by the Journal of the American Society of Nephrology.

Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, announced that it has entered into a strategic multi-year research collaboration with Moffitt Cancer Center for pre-clinical development of investigational tumor-infiltrating lymphocyte therapies.

Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population.

Karuna Therapeutics, Inc. today announced the appointment of Charmaine Lykins as chief commercial officer, effective November 29, 2021.

Anavex Life Sciences Corp. today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, is scheduled to participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021 at 12:10 p.m. ET.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced new long-term durability data from the Phase 1/2 studies of DTX401 for Glycogen Storage Disease Type Ia (GSDIa) and DTX301 for Ornithine Transcarbamylase (OTC) deficiency that were presented at the 14th International Congress of Inborn Errors of Metabolism (ICIEM).